Previous 10 | Next 10 |
After FibroGen (FGEN) shares collapsed 28% after-hours in reaction to certain disclosures of safety analyses from the roxadustat program, the FDA has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee ((CRDAC)) on July 15, 2021 to review the New Drug ...
Gainers: [[AKBA]] +12.1%. [[SYBX]] +7.1%. [[ARDX]] +5.2%. [[ODT]] +4.9%. [[BYND]] +4.2%.Losers: [[FGEN]] -29.2%. [[FIXX]] -10.2%. [[MAXN]] -6.8%. [[IONS]] -5.8%. [[OM]] -5.4%. For further details see: AKBA, SYBX, FGEN and FIXX among after-hours movers
Akebia Therapeutics ([[AKBA]] +1.9%) announced that it submitted a New Drug Application (“NDA”) to the FDA seeking approval for Vadadustat for the treatment of anemia due to chronic kidney disease (“CKD”) in adults irrespective of their dialysis therapy.Within...
Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis PR Newswire CAMBRIDGE, Mass. , March 30, 2021 /PRNewswire/ -- Akebia Therapeutics ...
Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings PR Newswire CAMBRIDGE, Mass. , March 25, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a ...
Akebia Therapeutics (AKBA) announced that its collaborator, Japan Tobacco has received approval from the Pharmaceuticals and Medical Devices Agency in Japan for an additional indication of Riona tablets 250mg (Riona)Riona (generic name: ferric citrate hydrate) is therefore indicated in Japan ...
Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan PR Newswire CAMBRIDGE, Mass. , March 24, 2021 /PRNewswire/ -- Akebia Therapeutics, In...
Are These Robinhood Penny Stocks On Your Buy Or Sell List Right Now? As we end another week in March, both penny stocks and blue chips remain highly volatile. Overall this month has been quite bullish for many stocks under $5, yet broader markets continue trading sideways. Several facto...
The following slide deck was published by Akebia Therapeutics, Inc. in conjunction with this event. For further details see: Akebia Therapeutics (AKBA) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow
Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month Company Initiates Campaign to Honor Patients and Promote Awareness of Kidney Disease PR Newswire CAMBRIDGE, Mass. , March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq:...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on May 9, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Akebia Therapeutics ...
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...